KR910002451A - 메탄디포스폰산 유도체를 함유하는 국소투여용 약제 및 이의 용도 - Google Patents

메탄디포스폰산 유도체를 함유하는 국소투여용 약제 및 이의 용도 Download PDF

Info

Publication number
KR910002451A
KR910002451A KR1019900010205A KR900010205A KR910002451A KR 910002451 A KR910002451 A KR 910002451A KR 1019900010205 A KR1019900010205 A KR 1019900010205A KR 900010205 A KR900010205 A KR 900010205A KR 910002451 A KR910002451 A KR 910002451A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
formulation
therapeutic system
transdermal administration
diphosphonic acid
Prior art date
Application number
KR1019900010205A
Other languages
English (en)
Inventor
지오르지오 페리니 피에르
보엘미 카를로
하인리흐 스타흘 페터
그린 죠나단
Original Assignee
베르너 발데그
시바-가이기 에이지
글라슬, 자이트
헨켈 코만디트게젤샤프트 아우프 아크티엔
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르너 발데그, 시바-가이기 에이지, 글라슬, 자이트, 헨켈 코만디트게젤샤프트 아우프 아크티엔 filed Critical 베르너 발데그
Publication of KR910002451A publication Critical patent/KR910002451A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

메탄디포스폰산 유도체를 함유하는 국소투여용 약제 및 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 일반식(I)의 약제학적으로 허용되는 메탄 디포스폰산 유도체 및 이의 염을 함유하는, 국소 투여할 수 있는 약제학적 제제
    상기식에서, R1및 R2는 수소 또는 C1내지 C3알킬이다.
  2. 제1항에 있어서, 3-아미노-1-하이드록시프로판-1,1-디포스폰산 또는 약제학적으로 허용되는 이의염을 함유하는 제제.
  3. 제1항에 있어서, 3-디메틸아미노-1-하이드록시프로판-1,1-디포스폰산 또는 약제학적으로 허용되는 이의염을 함유하는 제제.
  4. 제1항에 있어서, 3-(N-메틸-N-n-프로필아미노)-1-하이드록시프로핀-1,1-디포스폰산또는 약제학적으로 허용되는 이의 염을 함유하는 제제.
  5. 제1항 내지 4항중 어느 한항에 있어서 ,크림제, 겔제, 연고제, 로션제, 페이스트제, 발포제, 팅크제, 마이크로유제 또는 용제 형태의 제제.
  6. 제1항 내지 제4항중 어느 한 항에 있어서, 경피투여용 다층 치료학적 시스템 형태의 제제.
  7. 제6항에 있어서, 경피 투여용 다층 치료학적 시스템이 (1) 활성성분 제형의 구성분중 연속층에 침투할 수 없는 밀폐된 이면 포일, (2) 활성 성분이 접착제 포일중에 미리 존재하지 않는 경우, 이면 포일에 이온 활성 성분용 저장기, (3) 접착제 층, 및 (4) 박리성 보호 포일을 함유하는 제제.
  8. 제1항 내지 4항, 6항 및 7항중 어느 한 항에 있어서, 매트릭스 또는 막 유형의 경피투여를 위한 다층 치료학적시스템 형태의 제제.
  9. 상기 실시예에서 기술한 약제학적 제제 및 이의 제조방법.
  10. 국소투여를 위해 일반식(I)의 화합물 또는 이의 염을 약제학적 조성물에 도입시킴을 특징으로 하여, 약제학적으로 허용되는 일반식(I)의 메탄디포스폰산 유도체의 흡수를 증가시키는 방법.
  11. 칼슘 과다혈증 및 골연화성 골 전이증의 치료에서 국소투여할 수 있는 제1항 내지 8항중 어느 한 항에 따른 약제학적 제제의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900010205A 1989-07-07 1990-07-06 메탄디포스폰산 유도체를 함유하는 국소투여용 약제 및 이의 용도 KR910002451A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH2795/89-0 1989-07-07
CH279589 1989-07-07

Publications (1)

Publication Number Publication Date
KR910002451A true KR910002451A (ko) 1991-02-25

Family

ID=4241754

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900010205A KR910002451A (ko) 1989-07-07 1990-07-06 메탄디포스폰산 유도체를 함유하는 국소투여용 약제 및 이의 용도

Country Status (13)

Country Link
EP (1) EP0407345A3 (ko)
JP (1) JPH0344396A (ko)
KR (1) KR910002451A (ko)
AU (1) AU638034B2 (ko)
CA (1) CA2020563A1 (ko)
DD (1) DD300353A5 (ko)
FI (1) FI903328A0 (ko)
HU (1) HU206267B (ko)
IE (1) IE902482A1 (ko)
MX (1) MX21453A (ko)
NZ (1) NZ234378A (ko)
PT (1) PT94610A (ko)
ZA (1) ZA905310B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100732454B1 (ko) * 2001-08-31 2007-06-27 재단법인 포항산업과학연구원 고온 엑스선 실험용 고온장치

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU670337B2 (en) 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
CA2669488A1 (en) * 2006-11-17 2008-05-22 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
EP1923049A1 (en) * 2006-11-17 2008-05-21 Besins Healthcare Pharmaceutical compositions comprising a bisphosphonate compound
US11077194B2 (en) 2012-03-14 2021-08-03 Novan, Inc. Nitric oxide releasing pharmaceutical compositions
US10206947B2 (en) 2013-08-08 2019-02-19 Novan, Inc. Topical compositions and methods of using the same
US11813284B2 (en) 2013-08-08 2023-11-14 Novan, Inc. Topical compositions and methods of using the same
JP7090549B2 (ja) 2016-03-02 2022-06-24 ノヴァン，インコーポレイテッド 炎症のための治療用組成物およびその治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100732454B1 (ko) * 2001-08-31 2007-06-27 재단법인 포항산업과학연구원 고온 엑스선 실험용 고온장치

Also Published As

Publication number Publication date
NZ234378A (en) 1992-08-26
FI903328A0 (fi) 1990-07-02
MX21453A (es) 1994-01-31
JPH0344396A (ja) 1991-02-26
IE902482A1 (en) 1991-02-13
HU904127D0 (en) 1990-12-28
EP0407345A3 (en) 1991-07-24
DD300353A5 (de) 1992-06-04
AU638034B2 (en) 1993-06-17
ZA905310B (en) 1991-03-27
HUT54503A (en) 1991-03-28
PT94610A (pt) 1991-03-20
HU206267B (en) 1992-10-28
AU5870090A (en) 1991-01-10
CA2020563A1 (en) 1991-01-08
EP0407345A2 (de) 1991-01-09

Similar Documents

Publication Publication Date Title
US20030077301A1 (en) Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US20030072814A1 (en) Topical pharmaceutical composition for the treatment of warts
US20060002874A1 (en) Topical pharmaceutical composition to treat hyperpigmentation of the skin
KR960001373B1 (ko) 제약학적 활성 물질의 침투 증강용 2성분계 침투증강 조성물
EP0179277A1 (en) Medical composition for external application
US6821523B2 (en) Topical administration of pharmacologically active bases in the treatment of warts
EP0206291A3 (en) Sprayable pharmaceutical preparation for topical application
DK0535327T3 (da) Farmaceutisk præparat indeholdende felbinac
KR880000091A (ko) 국소용 약제학적 조성물 이의 제조방법 및 이의 용도
US4931283A (en) Menthol enhancement of transdermal drug delivery
KR890000183B1 (ko) 경피 침투가 증진된 생리학적 활성 제제 및 그의 제조방법
CA2181364A1 (en) Preparation for percutaneous absorption
US6943197B2 (en) Topical administration of pharmacologically active bases in the treatment of inflammatory dermatoses
NZ209843A (en) Transdermal delivery system for administration of nitroglycerin
SE8001599L (sv) Transdermalt medicineringssystem for isosorbiddinitrat
KR910002451A (ko) 메탄디포스폰산 유도체를 함유하는 국소투여용 약제 및 이의 용도
KR20000049125A (ko) 외용 국소 마취제
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR880002518A (ko) 소염제 조성물
JPS60163811A (ja) プロプラノロ−ル含有外用貼付剤
KR910021238A (ko) 켈로이드 치료제
KR920700624A (ko) 피부도포용 수용성 비타민 a제제
US4666926A (en) Transdermal formulations
KR900016156A (ko) 퀴녹살린 유도체 및 궤양치료제
JPS63227524A (ja) 外用消炎鎮痛剤

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid